Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is
emerging as a promising biomarker for immunotherapy response in cancer patients. TMB …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …

Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of
lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung …

Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …

Immune-related adverse events (irAEs), caused by anti-PD-1/PD-L1 antibodies, can lead to
fulminant and even fatal consequences and thus require early detection and aggressive …

Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival in …

Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …

Introduction For patients with recurrent SCLC, topotecan remains the only approved second-
line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open …